Navigation Links
GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
Date:3/6/2013

ZURICH-SCHLIEREN, Switzerland, March 6, 2013 /PRNewswire/ -- Following recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals, GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced that Gerd Zettlmeissl, will be appointed Chairman of the Board of Directors, effective June 2013, when Michel Greco steps down from the Chairmanship.

Gerd Zettlmeissl has more than 20 years of experience in developing and commercializing vaccines. He spent almost 10 years in executive positions at Intercell AG, first as its Chief Operating Officer from 2001 to 2005 and then as its Chief Executive Officer from 2005 until May  2011. Under his leadership, the company received international approval for the novel Japanese encephalitis vaccine, IXIARO®/JESPECT®, formed major strategic alliances with leading pharmaceutical companies, completed several financings, was elected as 'Technology Pioneer' at the World Economic Forum in 2009 and received the European Biotechnica Award in 2006. Before his tenure at Intercell, he served as the international Head of Industrial and Quality Operations at Chiron Vaccines, and Managing Director of Chiron Behring GmbH & Co. He currently serves on the Boards of several biotechnology companies including Aeras, an organization dedicated to the development of tuberculosis vaccines. He holds a Doctorate from the University of Regensburg.

"Having worked very closely with Gerd at Intercell for a number of years, I am convinced that he will bring a wealth of development experience and entrepreneurial spirit to this very promising company," said Michel Greco , Chairman of the Board of Directors of GlycoVaxyn. "After having chaired the Board for more than seven years, I will work very closely with Gerd to ensure a smooth transition."

Philippe Dro , Chief Executive Officer of GlycoVaxyn added, "The changes to the Board and the appointment of Gerd will contribute to support GlycoVaxyn's strategic ambitions to become a major player in the development of a new generation of vaccines, particularly following our recently signed collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals. We know Gerd very well and share with him a common passion for the development of innovative vaccines. After several years of close collaboration with Michel on this exciting project over the years, I would like to sincerely thank him, on behalf of the whole team, for his strong commitment and support."

About GlycoVaxyn AGGlycoVaxyn is a privately-funded company developing a portfolio of novel bio-conjugate vaccines against common severe bacterial infections produced with its unique, proprietary in vivo glycosylation platform. With this platform, the company can develop and produce immunogenic glycoprotein conjugates in a biological process that circumvents many of the challenges and uncertainties involved in currently/chemical used methods. In addition to the clinical stage Shigella vaccine, lead programs in preclinical stage are aimed at the prevention of hospital acquired Staphylococcus aureus infections. GlycoVaxyn recently entered collaborations with GlaxoSmithKline Biologicals and Janssen Pharmaceuticals. GlycoVaxyn is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners.  For further information, visit www.glycovaxyn.com.Contacts:Robert FlammGlycoVaxyn AG

Russo Partners, LLCTel: +41 44 733 8595

Tel: +212-845-4226media@glycovaxyn.com

robert.flamm@russopartnersllc.com


'/>"/>
SOURCE GlycoVaxyn AG
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Bayer CropScience Announces Seed Innovation at Pollinator Summit
2. Alexandria Real Estate Equities, Inc. Announces Long-Term Lease with Leading Global Commercial-Stage Oncology Company, Onyx Pharmaceuticals, Inc., for New Build-to-Suit Facility in South San Francisco, California
3. lifeIMAGE Announces No-Cost Service for Hospitals to Give Patients Secure Access to Medical Imaging, Pledges Support for the Blue Button Initiative
4. Macrogen Corp. Announces the Inception of Macrogen Clinical Laboratory (MCL)
5. Quantum Cures Announces Breakthrough Approach for Researchers Seeking Cures for Orphan and Rare Diseases
6. Pittcon Announces the 2013 Pittsburgh Conference Memorial National College Grant Awardees
7. Research and Markets Announces Addition of the "Risk - Reward of Developing a Herceptin Biosimilar - A Thorough Assessment" Report to its Offering
8. Research & Markets Announces the Release of 'Analog Devices ADXL362 3-axis Micropower MEMS Accelerometer Reverse Costing Analysis'
9. Research & Markets Announces the Release of STMicroelectronics LSM303D 6-Axis Electronic Compass - Reverse Costing Analysis
10. Pamlab Announces Agreement for Sale of Business to Nestle Health Science
11. Elsevier Announces the Launch of a New Journal: Methods in Oceanography
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... innovative medical technologies, services and solutions to the healthcare market. The company's primary ... various distribution, manufacturing, sales and marketing strategies that are necessary to help companies ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a ... eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research ... by providing practical tips, tools, and strategies for clinical researchers. , “The landscape ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):